Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-23T20:21:29.326Z Has data issue: false hasContentIssue false
  • English
  • Français

Monoclonal Antibody Therapy and Progressive Multifocal Leukoencephalopathy

Published online by Cambridge University Press:  02 December 2014

Alan C. Jackson
Alan C. Jackson*
Affiliation:
University of Manitoba, Winnipeg, Manitoba, Canada
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Canadian Journal of Neurological Sciences , Volume 38 , Issue 4 , July 2011 , pp. 545 - 546
Copyright
Copyright © The Canadian Journal of Neurological 2011

References

1.Engsig, FN, Hansen, AB, Omland, LH, et al.Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis. 2009;199:77–83.Google Scholar
2.Rice, GP, Hartung, HP, Calabresi, PA.Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology. 2005;64:1336–42.CrossRefGoogle ScholarPubMed
3.Krumbholz, M, Meinl, I, Kumpfel, T, Hohlfeld, R, Meinl, E.Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology. 2008;71:1350–4.Google Scholar
4.O’Connor, PW.Use of natalizumab in multiple sclerosis patients. Can J Neurol Sci. 2010;37:98–104.Google Scholar
5.Adelman, B, Sandrock, A, Panzara, MA.Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med. 2005;353:432–3.CrossRefGoogle ScholarPubMed
6.Langer-Gould, A, Atlas, SW, Green, AJ, Bollen, AW, Pelletier, D.Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375–81.CrossRefGoogle Scholar
7.Kleinschmidt-DeMasters, BK, Tyler, KL.Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369–74.CrossRefGoogle ScholarPubMed
8.Van, AG, Van, RM, Sciot, R, et al.Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353:362–8.Google Scholar
9.Clifford, DB, De Luca, A, Simpson, DM, Arendt, G, Giovannoni, G, Nath, A.Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9:438–46.Google Scholar
10.Yousry, TA, Major, EO, Ryschkewitsch, C, et al.Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354:924–33.Google Scholar
11.Biogen Idec (2011) Tysabri, PML monthly update - May 2011.Google Scholar
12.Carson, KR, Evens, AM, Richey, EA, et al.Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834–40.CrossRefGoogle ScholarPubMed
13.Sandrock, A, Hotermans, C, Richman, S, et al.Risk stratification for progressive multifocal leukoencephaloathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV antibody status (Abstract). Neurology. 2011; 76(Suppl 4):A278.Google Scholar
14.Tan, CS, Koralnik, IJ.Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol. 2010;9:425–37.Google Scholar
15.Keene, DL, Legare, C, Taylor, E, Gallivan, J, Cawthorn, GM, Vu, D.Monoclonal antibodies and progressive multifocal leukoencephalopathy. Can J Neurol Sci. 2011;38(4):565–71.Google Scholar
16.Korman, BD, Tyler, KL, Korman, NJ.Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol. 2009;145: 937–42.Google Scholar
17.Gorelik, L, Lerner, M, Bixler, S, et al.Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68: 295–303.Google Scholar
18.Chen, Y, Bord, E, Tompkins, T, et al.Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med. 2009;361:1067–74.Google Scholar
19.Jilek, S, Jaquiery, E, Hirsch, HH, et al.Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol. 2010;9: 264–72.Google Scholar